drugset / Trial / NCT01450098

A Study of LY2484595 in Healthy Subjects

NCT01450098

Phase 1 Completed 39 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study will be to evaluate the safety of a single dose of LY2484595 and to compare the amount of LY2484595 in the blood of healthy non-Asian subjects, Chinese subjects, and first-generation Japanese subjects after receiving a single oral dose of LY2484595 in a fasted state, after eating a low-fat meal, and after eating a high-fat meal.

Timeline

Start
2011-10
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Evacetrapib Small molecule 100 mg Oral
Subject Evacetrapib Small molecule 200 mg Oral
Subject Evacetrapib Small molecule 300 mg Oral

Indications

No indication recorded.